Navigation Links
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Date:2/11/2013

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.  

Brian M. Culley , Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter.  We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose." 

Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."

The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers.  The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial.  Sixty subjects will be enrolled.  Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions.  The Company is recruiting subjects in EPIC, a randomized, double-blind, placebo-controlled phase 3 study of ANX-188 in patients with sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing of completion and announcement of results of the TQT study. Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and expectations indicated by the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the potential for delays in the commencement or completion of clinical studies, including as a result of difficulties with opening trial sites or enrolling study subjects or being subject to a "clinical hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; ADVENTRX's reliance on contract research organizations (CROs) to conduct its clinical studies and on other third parties to assist with important aspects of its development and regulatory activities for ANX-188 and the potential for such third parties to fail to perform as expected or required; the risk that clinical studies, including EPIC and the TQT study, are not successfully executed and/or do not successfully demonstrate the safety or efficacy of the investigational drug; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; the risk that even if clinical studies of an investigational drug in one indication are successful, clinical studies of the same investigational drug in another indication may not be successful; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower-return development paths if it is unable to raise sufficient additional capital as needed; the risk that the FDA does not grant marketing approval of ADVENTRX's product candidates, including ANX-188, on a timely basis, or at all; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Announces Establishment of Regulatory Advisory Board
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
5. Applied Genetics Initiates Commercial Operation
6. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
9. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
10. Positive Clinical Study Results for BSPs HyperQ Technology
11. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):